Entrada Therapeutics Inc (TRDA) returns
Entrada Therapeutics returns over 5 years
$1,000 invested in Entrada Therapeutics five years ago was worth $189.35 at the close on October 30, 2026, with dividends reinvested: an average return of -28.3% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -28.6% | — | $714.17 | -0.9% |
| 3 months | -33.0% | — | $669.87 | +2.1% |
| Year to date | -55.9% | — | $441.15 | +11.7% |
| 1 year | -34.3% | — | $657.25 | +12.4% |
| 3 years | -70.5% | -33.4% | $295.05 | +88.5% |
| 5 years | -81.1% | -28.3% | $189.35 | +76.0% |
Entrada Therapeutics return by calendar year
| Year | TRDA | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -55.9% | +11.7% | -67.6% |
| 2025 | -40.5% | +17.7% | -58.3% |
| 2024 | +14.6% | +24.9% | -10.3% |
| 2023 | +11.6% | +26.2% | -14.6% |
| 2022 | -21.0% | -18.2% | -2.9% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: TRDA financials
No forecast, no recommendation. This page describes Entrada Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.